Model-based Clinical Efficacy Prediction and Study Design Support for VIS410, a Novel Neutralizing mAb, in Combination with Oseltamivir, in Hospitalized Patients with Influenza A
February 23, 2018 | International Society for Influenza and Respiratory Viruses (ISIRV) Antiviral Drug Development Conference
